Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Semaglutide D Dose 1 · 3 trials · 4 indications
Measured in Percentage
h∙nmol/L
nmol/L
h \* nmol/L
| Arm | Type | Description |
|---|---|---|
| Semaglutide | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Group 1 Sequence 1 | EXPERIMENTAL | Crossover arm |
| Group 1 Sequence 2 | EXPERIMENTAL | Crossover arm |
| Group 2 Sequence 1 | EXPERIMENTAL | Crossover arm |
| Group 2 Sequence 2 | EXPERIMENTAL | Crossover arm |
| Group 3 Sequence 1 | EXPERIMENTAL | Crossover arm |
| Group 3 Sequence 2 | EXPERIMENTAL | Crossover arm |
| Part A: Oral semaglutide | EXPERIMENTAL | Four different formulations of oral semaglutide are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days |
| Part B: NNC0385-0434 | EXPERIMENTAL | Four different formulations of NNC0385-0434 are investigated. One formulation given for 10 days before participants receive a different formulation for 5 days |
| Name | Type | Description |
|---|---|---|
| Semaglutide D Dose 1 | DRUG | Tablet given orally |
| Semaglutide D Dose 2 | DRUG | Tablet given orally |
| Semaglutide D Dose 3 | DRUG | Tablet given orally |
| Semaglutide C Dose 4 | DRUG | Tablet given orally |
| Semaglutide C Dose 5 (50 mg) | DRUG | Tablet given orally |
| Placebo (Semaglutide C) | DRUG | Tablet given orally |
| Placebo ( Semaglutide D) | DRUG | Tablet given orally |
| Semaglutide Dose 4 | DRUG | Tablet given orally |
| Semaglutide Dose 5 | DRUG | Tablet given orally |
| Semaglutide Dose 6 | DRUG | Tablet given orally |
| Semaglutide D | DRUG | Tablet given orally |
| Semaglutide G | DRUG | Tablet given orally |
| Semaglutide H | DRUG | Tablet given orally |
| Semaglutide I | DRUG | Tablet given orally |
| NNC0385-0434 B | DRUG | Tablet given orally |
| NNC0385-0434 C | DRUG | Tablet given orally |
| NNC0385-0434 D | DRUG | Tablet given orally |
| NNC0385-0434 E | DRUG | Tablet given orally |
Inclusion Criteria: * Male or female, aged 18-65 years (both inclusive) at the time of signing informed consent * Body mass index between 30.0 and 45.0 kilogram per meter square (kg/m\^2) (both inclusive) Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pregnant o...
Semaglutide D Dose 1 is an investigational small molecule being developed by Novo Nordisk A/S for metabolic conditions, including obesity and healthy volunteer studies. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and remains under investigation for safety and efficacy.
Semaglutide D Dose 1 is a small molecule developed for metabolic conditions. Its specific molecular target has not been disclosed in available information, so its exact mechanism of action is not detailed here.
Semaglutide D Dose 1 is developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting Phase 1 clinical trials to evaluate the drug's safety and tolerability in healthy volunteers and people with obesity.
Semaglutide D Dose 1 is in Phase 1 clinical development. It is an investigational drug, meaning it is not FDA approved and is still being studied in clinical trials. The drug has received an accelerated approval designation, but this does not indicate it has been approved for commercial use.
Semaglutide D Dose 1 has completed three Phase 1 trials: NCT05129891, NCT05227196, and NCT05236517. These studies evaluated the drug in healthy volunteers, people with type 2 diabetes, and individuals with obesity. All trials are completed, with a total enrollment of 930 participants across Canada, Germany, and the United States.
Semaglutide D Dose 1 is a form of oral semaglutide, as indicated by clinical trial NCT05227196, which compares two different forms of oral semaglutide. However, the drug is distinct from other semaglutide formulations and is being studied specifically as a small molecule for metabolic conditions.